Metronidazole has been the treatment of choice for trichomoniasis for more than 10 years. Carneri and co-workers (1969) described another nitromidazole compound 'nitrimidazine' (1-N (B-ethylmorpholine)-5-nitroimidazole) which was found to be active systemically after oral administration. They demonstrated that effective trichomonicidal levels in urine and blood could be obtained after oral ingestion of 250 mg. of the compound, and further suggested that nitrimidazine was active topically.
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A clinical trial of the systemic efficacy of this compound is reported below.
Method 100 women attending a venereal diseases clinic who were found to be harbouring T. vaginalis in the vaginal secretion were each given one tablet of 250 mg. nitrimidazine orally twice daily for 6 days. Where possible, their sexual partners were also given the same dosage of the drug.
Diagnosis was based on detection of the parasite in a 'hanging drop' sample of the vaginal secretion and on culture in Feinberg-Whittington medium. The patients were later re-examined, by the hanging drop method at the least, on the 2nd and 6th days after starting to take the drug, and culture was carried out 4 to 6 weeks after the completion of treatment. Patients who failed to return for final assessment of cure by culture were excluded from the trial. 
